⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616823 | 1.00 | — | — | |
| SCHEMBL694584 | 0.91 | — | — | |
| SCHEMBL694585 | 0.91 | — | — | |
| SCHEMBL694583 | 0.91 | — | — | |
| Perchlorate SCHEMBL10494950 | 0.83 | — | — | |
| Perchlorate SCHEMBL11496469 | 0.83 | — | — | |
| SCHEMBL23777955 | 0.71 | — | — | |
| SCHEMBL34466738 | 0.71 | — | — | |
| SCHEMBL11899708 | 0.71 | — | — | |
| SCHEMBL12470560 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087399-A1 | 2-(4-PIPERIDYL)-6-(IMIDAZO[1,2-B]PYRIDAZIN-6-YL)THIENO[3,2-B]PYRIDINE DERIVATIVES THAT REDUCE THE PROTEIN LEVEL OF HUNTINGTIN (HTT) FOR THE TREATMENT OF HUNTINGTON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108509-A1 | 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4674852-A1 | PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE | Innovstone Therapeutics Limited (CN) | 2026-01-07 | — | — | EP | disclosed |
| US-20250270230-A1 | NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL | BOEHRINGER INGELHEIM INT (DE) | 2025-08-28 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| WO-2025131986-A1 | NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-4153652-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-11344029-B2 | Heterocyclic compound and composition containing same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-31 | — | — | US | disclosed |